



**Subscribe** to follow us @ILPMP on YouTube

[View as Webpage](#)

## On the Radar: Illinois Legislature Passes Stricter Rules for Accessing Prescription Data, Awaits Governor's Signature

The Illinois Senate and House have passed **HB 5373**, a bill that states that ordering, prescribing, dispensing, administering, or paying for controlled substances, including opioids, shall not be predetermined by specific morphine milligram equivalent guidelines for chronic pain patients. In addition, this bill eliminates ambiguity by explicitly prohibiting arbitrary limits and requiring adherence to current evidence-based guidelines. This bill also clarified ILPMP authority in context to the ILPMP Peer Review Committee (PRC), and outlined new requirements for authorized data requestors to obtain confidential data from the ILPMP. The bill now awaits the Governor's signature. If signed into law, it will take effect immediately, amending the Illinois Controlled Substance Act.

Under the new amendment, authorized data requests for ILPMP confidential information must be supported by one of the following:

- A valid court order or subpoena, or
- An administrative subpoena issued specifically by the Department of Financial and Professional Regulation

The amendment aims to ensure all requests are legally documented, reducing the risk of unauthorized access to sensitive patient data.

Other changes addressed include:

- Specifies that decisions regarding treatment with controlled substances, including opioids, should not be restricted by CDC Morphine Milligram Equivalent guidelines, unless required under federal law.
- Language stating ILPMP PRC retains full authority to use MME threshold for clinical oversight and monitoring.
- Adds trained designee may review and release ILPMP information upon review.
- Confidential information shared from Opioid Treatment Programs or

confidential information otherwise protected under federal confidentiality of substance use disorder patient records regulations under 42 CFR Part 2 shall not be included in the information shared.

For more information, you can view the full text of [HB 5373](#). The ILPMP is exploring options to receive this the supporting legal documentation electronically and further guidance is forthcoming.

## Illinois Prescription Monitoring Program Awarded \$1 Million Grant

The Illinois Department of Human Services' (IDHS) Illinois Prescription Monitoring Program has successfully applied for and been awarded a grant from the Bureau of Justice Assistant (BJA), Office of Justice Programs, Harold Rogers Prescription Drug Monitoring Program. The grant totals \$1,000,000 and will be allocated over a 24-month period.

The funding will support several key initiatives, including:

- Enhancing the quality and accuracy of ILPMP data.
- Assessing the efficiency and effectiveness of the ILPMP.
- Developing and disseminating educational materials.
- Facilitating the electronic sharing of prescription monitoring information among states.

These initiatives aim to strengthen the ILPMP's capabilities and promote better healthcare outcomes withing the designated project timeframe.


## DEA Releases 2024 Updated Drugs of Abuse Guide



U.S. Department of Justice  
Drug Enforcement Administration

# Drugs of Abuse

A DEA RESOURCE GUIDE / 2024 EDITION



The U.S. Drug Enforcement Administration (DEA) has published the 2024 edition of **Drugs of Abuse: A DEA Resource Guide**. This guide serves as a reliable resource on the most commonly used and misused drugs in the United States. Released periodically, *Drugs of Abuse* provides scientific information on the harms and effects of drug use, including their impact on the body and mind, overdose risks, origins, legal status, and other critical factors.

The 2024 edition builds upon the 2022 publication, offering updated details on emerging trends in drug misuse and abuse. It includes information on substances such as fentanyl, methamphetamine, marijuana, concentrates, vaping products, stimulants, and counterfeit pills. The guide also outlines U.S. drug regulations, including drug scheduling and chemical controls.

Recognizing the importance of education in preventing substance abuse, the guide is designed for use by medical professionals, law enforcement, educators, families, and communities. It provides access to additional drug education and prevention resources, including the DEA's websites: **DEA.gov** and **GetSmartAboutDrugs.com**.

[DEA Drugs of Abuse Guide](#)

## ILPMP Releases Fiscal Year 2024 Annual Report

The ILPMP has released its Fiscal Year 2024 (FY24) Annual Report,

highlighting significant achievements in the monitoring of Schedule II-V controlled substances, selected drugs of interest, and other health information.

Through these efforts, the ILPMP continues to prioritize patient safety with the program's comprehensive approach and ongoing enhancements that reflect its dedication to addressing the challenges of substance use and ensuring the well-being of Illinois residents.

[ILPMP FY 2024 Annual Report](#)



## 2024 ANNUAL REPORT

ON THE ILLINOIS PRESCRIPTION MONITORING PROGRAM

 [DHS.PMP@Illinois.gov](mailto:DHS.PMP@Illinois.gov)

 [ILPMP.ORG](http://ILPMP.ORG)

## Educational Resources

### **Opioid Replacement Myths**

Buprenorphine / naloxone is a life-saving medication when used for opioid use disorder (OUD). Unfortunately, this drug is still misunderstood by both health care professionals and lay persons. This short, animated video briefly discusses the myths surrounding opioid replacement therapy for the treatment of OUD. Brought to you by the Southern Illinois University Edwardsville School of Pharmacy and the Illinois Prescription Monitoring Program.



MYTH #1: PERSONS USING OPIOID REPLACEMENT PRODUCTS FOR OPIOID USE DISORDER AREN'T REALLY IN RECOVERY

MYTH #2: BUPRENORPHINE PRODUCTS ARE OVER-PRESCRIBED AND ABUSED

MYTH #3: OVERDOSE WITH BUPRENORPHINE HAPPENS AS FREQUENTLY AS WITH OTHER OPIOIDS

MYTH #4: USING BUPRENORPHINE WITHOUT GETTING THERAPY DOESN'T COUNT AS TREATMENT FOR OPIOID USE DISORDER

## Newly Released, FREE, Continuing Education Available for Pharmacists and Pharmacy Technicians on the Importance of PMP Data Integrity

Take advantage of this free ACPE accredited educational opportunity providing 1 hour of continuing education for pharmacists and pharmacy technicians. This program, developed in partnership with NASCSA and 12 prescription monitoring program (PMP) administrators, analyzes the importance and value of complete, accurate data reported by dispensers to PMPs and assesses the impact of intentional or non-intentional data entry errors and data omissions on patient safety. It also discusses the downstream impacts of pharmacy-reported PMP data on clinical decision-making processes and helps pharmacy staff identify and implement changes that can be made in their practice setting to improve PMP data integrity.

Visit <https://ce.talemhealth.com/a/MWEORC>

**If you received credit for this CE prior to 10/22/24, you are still able to retake the CE and receive credit.**


[Click for more CE Information](#)

# Navigating Pain Management, Safe Opioid Prescribing, and Opioid Use Disorder

A three-hour program designed to meet the educational needs for physicians, nurses, and pharmacists. The program is accredited in 6, 30-minute modules.

SOUTHERN ILLINOIS UNIVERSITY  
EDWARDSVILLE

**ILPMP**  
Illinois Prescription Monitoring Program



## Continuing Education Program

### Navigating Pain Management, Safe Opioid Prescribing, and Opioid Use Disorder

Session 1: Pain taxonomy, pathogenesis, and assessment  
Session 2: Developing a patient-centered pain treatment plan  
Session 3: Non-opioid analgesics: Evidence and clinical Pearls  
Session 4: Opioid analgesics: From A to Z  
Session 5: Clinical use of opioids: Safe prescribing and monitoring  
Session 6: The exit strategy: When the treatment becomes the problem







Faculty:  
June Oliver, MSN, APRN/CNS  
Laura Meyer-Junco, PharmD, BCPS, FASCP  
Chris Herndon, PharmD, BCACP, FCCP  
Camille Dunkley, MD, MHA, MS  
Noah Cooperstein, MD

[Prescriber Registration](#)

## ILPMP.ORG & IL PMPnow Monthly Data

### WEBSITE DATA DECEMBER 2024



					
183	94,213	71,644	275,069	1,810	11,404,675
NEW USERS IN DECEMBER	TOTAL USERS	TOTAL ILPMP PRESCRIBER USERS	TOTAL ILPMP WEBSITE REQUESTS	TOTAL IL PMPNOW CONNECTIONS	TOTAL IL PMPNOW REQUESTS

# Contact Information

If you have questions about the information that appears in this update or suggestions for future content, please email [dhs.pmp@illinois.gov](mailto:dhs.pmp@illinois.gov). Visit [www.ilpmp.org](http://www.ilpmp.org) for more information.



*The Illinois Prescription Monitoring Program (ILPMP) is an electronic database that collects, tracks, and stores reported dispensing data on Schedule II-V controlled substances, selected drugs of interest, and other health information. The Illinois Department of Human Services oversees the ILPMP, authorized by the Illinois Controlled Substances Act (720 ILCS 570/316). The ILPMP adheres to HIPAA and all access, disclosure, and confidentiality provisions of Illinois Law.*

Illinois Prescription Monitoring Program | 401 North Fourth Street | Springfield, IL 62702 US

[Unsubscribe](#) | [Update Profile](#) | [Constant Contact Data Notice](#)



Try email marketing for free today!